What Is the Wolverine Stack?
The "Wolverine Stack" is a term used in research communities to describe a combination of peptides selected for their complementary and synergistic effects on tissue repair, nerve regeneration, and systemic recovery. The name comes from the Marvel character whose defining trait is near-instant healing — and while the research obviously doesn't support anything that dramatic, the compounds in this stack represent some of the most studied peptides for accelerating recovery from injury, surgery, and chronic tissue damage.
The core stack consists of BPC-157 and TB-500, often extended with GHK-CU for connective tissue remodeling and NAD+ for cellular energy and neuroprotection. This article breaks down what each compound contributes, how the mechanisms interact, and what published research shows about combining them.
Why Combine These Peptides?
Each compound in the stack targets different aspects of the healing process. Using them together creates overlapping coverage across the key mechanisms of tissue repair:
| Mechanism | BPC-157 | TB-500 | GHK-CU | NAD+ |
|---|---|---|---|---|
| Angiogenesis (new blood vessels) | ✅ Strong | ✅ Strong | Moderate | — |
| Collagen synthesis | ✅ | ✅ | ✅ Strong | — |
| Nerve regeneration | ✅ Strong | ✅ | — | ✅ Strong |
| Anti-inflammatory | ✅ Strong | ✅ | ✅ Strong | ✅ |
| Systemic distribution | Local focus | ✅ Wide | Moderate | ✅ Wide |
| Cellular energy (mitochondria) | — | — | — | ✅ Strong |
| Muscle cell repair | ✅ | ✅ Strong | — | ✅ |
| Gut/GI repair | ✅ Strong | — | — | — |
BPC-157: The Cornerstone
BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide derived from a gastric protective protein. It is the most extensively published peptide for soft tissue and nerve repair and forms the foundation of the Wolverine stack.
Key mechanisms:
- Upregulates VEGFR2 → promotes new blood vessel formation to injury sites
- Activates FAK-paxillin pathway → accelerates tendon and ligament fibroblast migration to injury
- Modulates nitric oxide system → reduces inflammation and improves blood flow
- Peripheral nerve regeneration → multiple sciatic crush models show significantly faster functional recovery
- GI tract protection and repair → strong evidence for gastric ulcer, gut permeability, and IBD models
Research areas: Tendon, ligament, muscle, nerve, bone, gut, brain (neuroprotective effects in stroke models)
TB-500: Systemic Reach
TB-500 is a synthetic version of Thymosin Beta-4, a protein involved in actin regulation, cell migration, and tissue repair. Where BPC-157 tends to produce strong local effects, TB-500 distributes widely throughout the body — making it particularly valuable for systemic or multi-site injury protocols.
Key mechanisms:
- Actin sequestration → regulates cell migration and repair signaling at injury sites
- Promotes satellite cell activation → accelerates muscle fiber regeneration
- Remyelination in CNS injury models → oligodendrocyte-mediated myelin repair
- Angiogenic and anti-inflammatory → complements BPC-157's vascular effects
- Reduces scar tissue formation → promotes clean tissue remodeling vs. fibrotic repair
The BPC-157 + TB-500 combination provides both local, targeted repair (BPC-157) and broad, systemic healing support (TB-500) — which is why they're consistently paired in research protocols targeting complex or multi-tissue injuries.
GHK-CU: Connective Tissue and Skin Remodeling
GHK-CU (Copper Peptide) extends the Wolverine stack into the connective tissue layer — tendons, ligaments, fascia, and skin — through its collagen-specific mechanisms. For researchers studying injuries involving the structural matrix (tendon tears, ligament damage, post-surgical recovery), GHK-CU adds a targeted collagen remodeling dimension that BPC-157 and TB-500 don't fully cover.
- Directly stimulates collagen I, III, and IV synthesis via fibroblast activation
- Downregulates TGF-β1 → reduces excessive scar/fibrotic collagen deposition
- Promotes elastin and glycosaminoglycan production
- Anti-inflammatory via TNF-α and IL-1β suppression
NAD+: Cellular Fuel for Recovery
NAD+ completes the stack by addressing the energy demands of tissue repair. Healing is metabolically expensive — fibroblasts, satellite cells, and neurons all require sustained ATP production during repair phases. NAD+ depletion slows every repair process in the stack.
- Fuels mitochondrial ATP production in repair-active cells
- SIRT1/SIRT3 activation → reduces oxidative stress in injured tissue
- PARP-mediated DNA repair → addresses cellular damage at injury sites
- Neuroprotective via axonal degeneration delay — complements BPC-157's nerve regeneration effects
Published Research Protocol References
| Compound | Frequency (Research Models) | Typical Duration |
|---|---|---|
| BPC-157 | Once or twice daily | 2–4 weeks (acute); longer for chronic |
| TB-500 | 2x/week loading → 1x/week maintenance | 4–6 week loading phase |
| GHK-CU | Daily (subcutaneous) | Concurrent with BPC-157 phase |
| NAD+ | Daily or every other day | Ongoing through protocol |
What the Stack Is and Isn't
The Wolverine Stack represents a well-reasoned assembly of compounds with complementary mechanisms and a strong individual evidence base. It is not a magic recovery protocol — the healing timeframes in preclinical research don't translate directly to human outcomes, and no combination of peptides replaces the fundamental requirements of recovery: adequate sleep, protein intake, load management, and time.
What the research does support is that each compound in this stack has demonstrated meaningful effects on its target tissues in well-controlled preclinical models, and that the mechanistic combination provides coverage across the key processes of repair in a way no single compound can.
All four compounds — BPC-157, TB-500, GHK-CU, and NAD+ — are available at My Freedom Peptides, independently third-party verified at 99%+ purity through Freedom Diagnostics Testing.
All products sold by My Freedom Peptides are for research use only. Not intended for human consumption, medical treatment, or diagnostic use. This article is for informational and research purposes only and does not constitute medical advice.
The Freedom Files
Don’t Miss the Next Article
Join our email list for weekly research insights, new product drops, and exclusive deals.
Join the ListFrequently Asked Questions
What is the 'Wolverine Stack' in peptide research?
The Wolverine Stack refers to the co-administration of BPC-157 and TB-500 (thymosin β4 synthetic fragment), two peptides studied for complementary tissue repair mechanisms. The nickname reflects the regenerative character popularized in the research and biohacking communities.
How do BPC-157 and TB-500 mechanisms differ?
BPC-157 primarily promotes angiogenesis and modulates the nitric oxide/eNOS pathway to support wound healing and GI repair. TB-500 (Tβ4 fragment 17–23) enhances actin polymerization and cell migration, supporting myocyte and tendon fibroblast recruitment to injury sites.
Is there published research specifically on the co-administration of BPC-157 and TB-500?
Direct co-administration studies in peer-reviewed literature are limited; most evidence is extrapolated from separate BPC-157 and Tβ4 studies in overlapping tissue models. Researchers combining these compounds typically design their own protocols based on the individual pharmacology data.
What endpoints would a researcher measure in a BPC-157/TB-500 combination study?
Relevant endpoints include time to wound closure, tendon tensile strength at healing, histological collagen organization, CD31 endothelial cell density (angiogenesis), and actin cytoskeleton organization in harvested tissue sections.
What purity requirements apply when sourcing both peptides for research?
Both BPC-157 and TB-500 should meet ≥98% HPLC purity with mass spectrometry confirmation. Researchers should obtain lot-specific CoAs for both peptides and verify that the TB-500 sequence corresponds to thymosin β4 fragment 17–23 (LKKTETQ), not the full Tβ4 protein.
For research use only. Not intended for human consumption.
For research use only. Not intended for human consumption. These statements have not been evaluated by the Food and Drug Administration.